Literature DB >> 17575153

Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.

Xiao-Ning Guo1, Ashwani Rajput, Rebecca Rose, Jennie Hauser, Alexander Beko, Karen Kuropatwinski, Charles LeVea, Robert M Hoffman, Michael G Brattain, Jing Wang.   

Abstract

Mutations in the PIK3CA gene are common in human cancers, including colon cancer. We compared two pairs of colon cancer cells (HCT116 and DLD1) bearing only the wild-type (WT) or mutant (MUT) PIK3CA allele for their survival capacity under stress conditions in vitro as well as their metastatic properties in an in vivo orthotopic model. When subjected to growth factor deprivation stress (GFDS), the MUT PIK3CA cells displayed resistance to GFDS-induced apoptosis relative to the WT cells. Phosphatidylinositol 3-kinase (PI3K) and its downstream effector AKT were constitutively activated during stress conditions in the MUT PIK3CA cells but not in the WT cells. The MUT cells showed hypersensitivity to PI3K inhibition. Moreover, the proapoptotic protein Bax was expressed at a very high level in the WT PIK3CA cells, whereas it was almost undetectable in the MUT cells. Inhibition of Bax expression by small interfering RNA protected the WT PIK3CA cells from GFDS-induced apoptosis, suggesting an important role of Bax in GFDS-induced apoptosis. These results indicated that the MUT PI3K confers resistance to GFDS-induced apoptosis and that the MUT cells are more dependent on the PI3K pathway for survival. In vivo studies showed that the MUT PIK3CA-bearing cells were more metastatic than the WT cells in an orthotopic model of colon cancer. Taken together, these results suggest that MUT PI3K imparts a more aggressive phenotype in colon cancer cells and could be a potential therapeutic target for treatment of colon cancer patients bearing PIK3CA mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575153     DOI: 10.1158/0008-5472.CAN-07-0049

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

Authors:  Arantza Fariña Sarasqueta; Eliane C M Zeestraten; Tom van Wezel; Gesina van Lijnschoten; Ronald van Eijk; Jan Willem T Dekker; Peter J K Kuppen; Ines J Goossens-Beumer; Valery E P P Lemmens; Cornelis J H van de Velde; Harm J T Rutten; Hans Morreau; A J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-08-10       Impact factor: 6.730

2.  Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis.

Authors:  E Agarwal; C M Robb; L M Smith; M G Brattain; J Wang; J D Black; S Chowdhury
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

3.  The role of transforming growth factor-beta in suppression of hepatic metastasis from colon cancer.

Authors:  Chandrakanth Are; Neka Simms; Ashwani Rajput; Ashwani Rajupt; Michael Brattain
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

4.  Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.

Authors:  John J Arcaroli; Kevin S Quackenbush; Rebecca W Powell; Todd M Pitts; Anna Spreafico; Marileila Varella-Garcia; Lynne Bemis; Aik Choon Tan; Jaclyn M Reinemann; Basel M Touban; Arvind Dasari; S Gail Eckhardt; Wells A Messersmith
Journal:  Clin Cancer Res       Date:  2012-05-01       Impact factor: 12.531

5.  R-Spondin1/LGR5 Activates TGFβ Signaling and Suppresses Colon Cancer Metastasis.

Authors:  Xiaolin Zhou; Liying Geng; Degeng Wang; Haowei Yi; Geoffrey Talmon; Jing Wang
Journal:  Cancer Res       Date:  2017-09-22       Impact factor: 12.701

6.  Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells.

Authors:  Dasha E Kenlan; Piotr Rychahou; Vitaliy M Sviripa; Heidi L Weiss; Chunming Liu; David S Watt; B Mark Evers
Journal:  Mol Cancer Ther       Date:  2017-03-03       Impact factor: 6.261

Review 7.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

Review 8.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

9.  Ezrin expression and cell survival regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ashwani Rajput; Michelle Mathiesen; Ekta Agarwal; Audrey J Lazenby; Chandrakanth Are; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

10.  Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.

Authors:  Jing Wang; Ashwani Rajput; Julie L C Kan; Rebecca Rose; Xiao-Qiong Liu; Karen Kuropatwinski; Jennie Hauser; Alexander Beko; Ivan Dominquez; Elizabeth A Sharratt; Lisa Brattain; Charles Levea; Feng-Lei Sun; David M Keane; Neil W Gibson; Michael G Brattain
Journal:  J Biol Chem       Date:  2009-02-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.